Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy

Basit Öğe Kaydı
dc.authorscopusid57226624079
dc.authorscopusid57226431644
dc.contributor.authorÇavdar, Eyyüp
dc.contributor.authorİriağaç, Yakup
dc.date.accessioned2023-04-20T08:05:55Z
dc.date.available2023-04-20T08:05:55Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractBackground/aim: Lymphovascular invasion (LVI) is considered a high-risk factor for recurrence in early-stage breast cancer, hence examination of LVI in pathological samples is an absolute recommendation. We aim to investigate predictive factors of LVI in pre-neoadjuvant chemotherapy (NAC) patients with estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) molecular subtypes of breast cancer. Materials and methods: One hundred and thirty-four patients treated with NAC were included in this study who were ER+/HER2-. The clinical characteristics of the patients, the data obtained from the core needle biopsy before NAC and the LVI status in the pathology that examined after breast surgery were collected. Univariate and multivariate analysis were performed using the logistic regression model. Results: An examination of the association between LVI and clinical-pathological patient characteristics showed that advanced age (>40 years old) (p = 0.021), ductal histology (p = 0.039), and presence of axillary lymph node metastasis (p = 0.005) were predictors of LVI. Independent predictors of LVI in a multivariate logistic model included advanced age (p = 0.037), and the presence of axillary lymph node metastasis prior to NAC (p = 0.006). The median RFS (Recurrence-free survival) time was 22.8 months for all patients. RFS was shorter in patients with LVI (log-rank p = 0.037). Conclusion: Independent predictors of LVI are advanced age and lymph node positivity at the time of diagnosis. Our study is the first study that evaluates pre-NAC predictive factors of LVI in ER+/HER2-breast cancer patients treated with NAC. © TÜBİTAK.
dc.identifier.doi10.55730/1300-0144.5414
dc.identifier.endpage1117
dc.identifier.issn1300-0144
dc.identifier.issue4en_US
dc.identifier.pmid36326379
dc.identifier.scopus2-s2.0-85136783108
dc.identifier.scopusqualityQ3
dc.identifier.startpage1111
dc.identifier.trdizinid1144733
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5414
dc.identifier.urihttps://hdl.handle.net/20.500.11776/11101
dc.identifier.volume52
dc.identifier.wosWOS:000881194200029
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorÇavdar, Eyyüp
dc.institutionauthorİriağaç, Yakup
dc.language.isoen
dc.publisherTurkiye Klinikleri
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast cancer
dc.subjectchemotherapy
dc.subjectlymphovascular invasion
dc.subjectpredictive
dc.subjectalpha smooth muscle actin
dc.subjectCD34 antigen
dc.subjectcyclophosphamide
dc.subjectcytokeratin 7
dc.subjectdocetaxel
dc.subjectepirubicin
dc.subjectestrogen receptor
dc.subjectKi 67 antigen
dc.subjectpaclitaxel
dc.subjectprogesterone receptor
dc.subjectprotein p63
dc.subjectuvomorulin
dc.subjectadjuvant therapy
dc.subjectadult
dc.subjectaged
dc.subjectaging
dc.subjectArticle
dc.subjectaxillary lymph node
dc.subjectbreast cancer recurrence
dc.subjectcancer hormone therapy
dc.subjectdistant metastasis
dc.subjectechography
dc.subjectestrogen receptor-positive, HER2-negative breast cancer
dc.subjectfemale
dc.subjectfluorescence in situ hybridization
dc.subjectfollow up
dc.subjecthistology
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectlymph node biopsy
dc.subjectlymph node metastasis
dc.subjectlymph vessel metastasis
dc.subjectmajor clinical study
dc.subjectmultiple cycle treatment
dc.subjectneedle biopsy
dc.subjectneoadjuvant chemotherapy
dc.subjectnuclear magnetic resonance imaging
dc.subjectpositron emission tomography-computed tomography
dc.subjectprotein expression
dc.subjectrecurrence free survival
dc.subjectretrospective study
dc.subjectthorax radiography
dc.subjecttumor volume
dc.titlePredictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
11101.pdf
Boyut:
281.35 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu